Cardiovascular system and COVID-19: manifestations and therapeutics

The world is currently in the midst of a daunting global pandemic due to SARS-CoV-2 viral infection and associated COVID-19 disease. Healthcare professionals are tasked with the challenge of managing diverse multisystem clinical manifestations of this infection. Although acute hypoxic respiratory failure is the hallmark of severe COVID-19 disease, there have been diverse manifestations within the cardiovascular (CV) system that each pose unique therapeutic challenges. Of these manifestations, myocardial injury and right ventricular dysfunction are the most common, however, heart failure, circulatory shock, cardiomyopathy, arrhythmia, and vascular thrombosis have been noted as well. Furthermore, these CV related manifestations portend greater morbidity and mortality, which requires clinicians to be familiar with the most recent information to provide informed patient care. Although there are limited treatment options available for COVID-19, it is imperative that the potential cardiovascular implications of these therapies are considered in these patients. This review highlights the pathophysiological mechanisms of and therapeutics for CV manifestations of COVID-19 as well as the CV implications of proposed COVID-19 therapies. Since our hospital-based providers are the frontline caregivers battling this pandemic, the aim of this review is to assist with clinical decision-making for optimal patient outcomes while maintaining a safe environment for healthcare personnel.

Abstract licence: CC BY

1. 15.

   High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa · 2020

2. 20.

   Coronavirus disease 2019: What we know? · 2020

3. 24.

   Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) · 2020

4. 25.

   Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update · 2020

5. 53.

   Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 · 2020

6. 54.

   The unique characteristics of COVID-19 coagulopathy · 2020

59 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.